The updated warnings highlight a rare risk of heart inflammation in teen boys and young men, CBS News reported. The warning ...

Wall Street on Friday closed out a topsy-turvy week with losses, as concerns over fiscal debt and U.S. President Donald Trump's latest salvo of tariff threats weighed on sentiment. For the week, the S ...

Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr.

In a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

But when a dividend yield reaches ultrahigh levels, investors can feel a heightened level of uncertainty. Wondering if Pfizer ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...